For the Quarter Ending June 2026
Oxcarbazepine Prices in APAC
- In India, the Oxcarbazepine Price Index rose by 0.58% quarter-over-quarter, reflecting balanced demand and cost pass-through.
- The average Oxcarbazepine price for the quarter was approximately USD 53646.75/MT, supporting steady tender procurement.
- Oxcarbazepine Spot Price remained orderly despite intermediate cost pressure and production across Gujarat and Telangana.
- Oxcarbazepine Price Forecast points to modest gains from steady hospital tenders and restrained producer discounting.
- Oxcarbazepine Production Cost Trend shows upward pressure from imported bromine derivatives, higher freight and energy.
- Oxcarbazepine Demand Outlook is stable and inelastic with public hospital procurement and export bookings supporting.
- Oxcarbazepine Price Index reflected mild monthly gains as formulators restocked ahead of monsoon procurement cycles.
- Producers maintained comfortable inventories while PLI incentives cushioned margins, limiting abrupt Oxcarbazepine Price Index volatility.
Why did the price of Oxcarbazepine change in June 2026 in APAC?
- Elevated imported intermediate costs and higher freight increased landed conversion costs, pressuring ex-works Oxcarbazepine offers.
- Defensive restocking by hospitals and formulators ahead of procurement cycles supported Oxcarbazepine demand and pricing.
- Monsoon-related transport friction and port evacuation delays tightened near-term availability, enabling producers to pass through costs.
Oxcarbazepine Prices in North America
- Oxcarbazepine Spot Price strengthened during Q2 2026 as generic drug manufacturers replenished inventories and secured forward supplies.
- Oxcarbazepine Production Cost Trend increased due to higher costs of pharmaceutical intermediates, solvents, compliance requirements, and transportation expenses.
- Oxcarbazepine Demand Outlook remained positive as demand for antiepileptic medications and neurological treatments continued to support procurement activity.
- Oxcarbazepine Price Forecast indicates stable-to-firm pricing in the near term amid healthy pharmaceutical demand and controlled inventory levels.
- The Oxcarbazepine Price Index reflected bullish sentiment as distributors increased purchases to mitigate potential import delays.
- Pharmaceutical companies maintained normal operating rates while monitoring overseas API shipments and freight developments.
Why did the price of Oxcarbazepine change in June 2026 in North America?
- Strong procurement from generic and branded pharmaceutical manufacturers increased demand for Oxcarbazepine APIs.
- Rising costs of intermediates, solvents, and logistics elevated overall production and sourcing expenses.
- Inventory replenishment by distributors and healthcare suppliers supported firmer spot market conditions.
Oxcarbazepine Prices in Europe
- Oxcarbazepine Spot Price remained firm throughout Q2 2026 as pharmaceutical manufacturers maintained regular procurement schedules.
- Oxcarbazepine Production Cost Trend moved upward due to higher energy costs, chemical intermediate prices, and transportation expenses.
- Oxcarbazepine Demand Outlook remained constructive as healthcare providers and generic drug manufacturers sustained stable production activity.
- Oxcarbazepine Price Forecast suggests stable-to-firm movement amid healthy downstream demand and balanced inventories.
- The Oxcarbazepine Price Index reflected positive market sentiment as distributors replenished inventories ahead of anticipated procurement cycles.
- European buyers closely monitored API imports from Asia, where a significant share of pharmaceutical intermediates originated.
Why did the price of Oxcarbazepine change in June 2026 in Europe?
- Consistent demand from epilepsy and neurological drug manufacturers supported procurement activity.
- Higher energy, transportation, and raw material costs increased production and import expenses.
- Inventory restocking by pharmaceutical distributors and healthcare suppliers strengthened market sentiment.
For the Quarter Ending March 2026
Oxcarbazepine Prices in APAC
- In India, the Oxcarbazepine Price Index fell by 0.41% quarter-over-quarter, reflecting mild domestic supply easing.
- The average Oxcarbazepine price for the quarter was approximately USD 53338.48/MT, assessed from Ex-Vadodara transactions and sample lots.
- Ex-Vadodara availability tightened, lifting the Oxcarbazepine Spot Price and pressuring near-term seller bargaining positions noticeably.
- Higher landed costs for Chinese intermediates pushed the Oxcarbazepine Production Cost Trend upward, eroding short-term margins.
- Public hospital tender activity and neurologist switching supported a firm Oxcarbazepine Demand Outlook for early second quarter.
- Market guidance and inventory cycles inform a cautious Oxcarbazepine Price Forecast, expecting moderate gains and intermittent softening.
- Lean finished-goods inventories amplified the Oxcarbazepine Price Index volatility, amplifying exporters' willingness to prioritise overseas shipments.
- Rising regional power tariffs and longer port gate cycles supported firmer Oxcarbazepine pricing through increased conversion and logistics costs.
Why did the price of Oxcarbazepine change in March 2026 in APAC?
- Stronger public tendering and clinician switching increased demand, tightening local availability versus routine production levels.
- Higher landed intermediate costs and rising industrial power tariffs elevated production expenses, prompting sellers to lift quotes.
- Longer port gate cycles and constrained container clearances delayed feedstock deliveries, tightening intermediates supply chains.
Oxcarbazepine Prices in North America
- In the United States, the Oxcarbazepine Price Index showed slight fluctuations during the quarter, reflecting balanced supply conditions and steady pharmaceutical demand.
- The average Oxcarbazepine price trend was shaped by consistent procurement from healthcare providers and stable production output across the region.
- Oxcarbazepine Spot Price firmed toward March as inventories tightened marginally and suppliers balanced contract commitments with limited spot volumes.
- Oxcarbazepine Production Cost Trend increased slightly, influenced by higher costs of imported intermediates and energy inputs.
- Oxcarbazepine Demand Outlook remained steady, supported by ongoing prescriptions for epilepsy treatment and stable hospital procurement activity.
- Oxcarbazepine Price Forecast suggests moderate firmness, with supply discipline and steady demand maintaining market balance.
- Inventory levels at distribution and healthcare channels declined slightly toward the end of the quarter, shaping restocking behavior.
- Logistics conditions remained stable overall, though minor delays in imported intermediates affected supply timing.
Why did the price of Oxcarbazepine change in March 2026 in North America?
- Slight tightening in inventories and steady healthcare demand supported firmer spot conditions.
- Increased costs for imported intermediates and energy inputs placed upward pressure on production expenses.
- Minor supply chain delays influenced availability, prompting cautious supplier pricing.
Oxcarbazepine Prices in Europe
- In the European Union, the Oxcarbazepine Price Index recorded mild upward movement over the quarter, supported by stable pharmaceutical demand and controlled supply.
- The average Oxcarbazepine price trend reflected steady procurement patterns from hospitals and distributors, with limited volatility.
- Oxcarbazepine Spot Price increased slightly in March as import arrivals tightened and suppliers prioritized contractual deliveries.
- Oxcarbazepine Production Cost Trend rose modestly due to higher energy costs and increased expenses for sourcing intermediates.
- Oxcarbazepine Demand Outlook remained firm, driven by consistent use in neurological treatments and stable prescription rates.
- Oxcarbazepine Price Forecast indicates continued stability with a slight upward bias, supported by steady demand and controlled inventories.
- Inventory levels across key pharmaceutical hubs declined slightly toward quarter-end, influencing procurement strategies.
- Freight and logistics conditions remained largely stable, though occasional delays in supply chains impacted short-term availability.
Why did the price of Oxcarbazepine change in March 2026 in Europe?
- Reduced import availability and slight inventory drawdowns tightened supply conditions.
- Stable demand from healthcare sectors supported consistent purchasing activity.
- Rising costs of intermediates and energy contributed to mild upward pricing pressure.
For the Quarter Ending December 2025
APAC
- In India, the Oxcarbazepine Price Index fell by 2.48% quarter-over-quarter, reflecting surplus merchant supply pressure.
- The average Oxcarbazepine price for the quarter was approximately USD 53558.69/MT, per regional spot sources.
- Oxcarbazepine Spot Price firmed while the Price Index reflected tighter intermediate inflows and stabilizing demand.
- Oxcarbazepine Price Forecast indicates modest firmness near term as demand recovery offsets sporadic feedstock arrivals.
- Oxcarbazepine Production Cost Trend shows pressure from bromo-acetophenone and packaging energy inflation further compressing margins.
- Oxcarbazepine Demand Outlook remains positive as formulators restock for Q1 tenders, supporting measured offtake growth. Oxcarbazepine Price Index volatility eased as inventories normalized and export schedules limited immediate upward pressure.
- Major producers ran near-nameplate capacity while smooth port operations helped maintain stable spot availability regionally.
Why did the price of Oxcarbazepine change in December 2025 in APAC?
- Domestic formulators accelerated purchases ahead of Q1 tenders, tightening spot availability and marginally supporting ex-works offers.
- Longer customs clearances for Chinese intermediates delayed feedstock arrivals, constraining immediate production and tightening merchant supply.
- Elevated intermediate and energy costs compressed margins, prompting producers to withhold discounts and maintain firmer pricing.
North America
- Regional price indices softened slightly over the quarter due to cautious restocking and moderate merchant supply.
- Spot prices firmed modestly in certain regions as inventories tightened and formulators adjusted procurement.
- Import logistics and customs processing influenced short-term supply flows.
- Formulators and hospitals restocked conservatively, awaiting clarity on Q1 procurement cycles.
- Demand remained stable but measured, preventing sharp price swings.
- Near-term outlook indicates stable to mild firmness, supported by consistent production and normalized inventories.
- Export and import schedules are expected to moderate volatility over the next quarter.
Why December 2025 Prices Changed
- Moderate demand and inventory management limited price momentum.
- Logistics and intermediate supply fluctuations affected availability and supported cautious price adjustments.
Europe
- Europe’s price index remained broadly stable with minor softening in markets facing surplus merchant supply.
- Spot prices varied regionally, firming slightly where inventories tightened.
- Formulators and hospitals undertook measured restocking ahead of Q1 tenders, supporting modest offtake growth.
- Tender cycles and healthcare budgets influenced demand stability across EU markets.
- Near-term forecast suggests stable to mildly firm pricing, as normalized inventories offset sporadic intermediate arrivals.
- Volatility is expected to remain low, supported by balanced supply-demand dynamics.
Why December 2025 Prices Changed
- Moderate demand and controlled restocking prevented sharp price increases.
- Delayed intermediates and higher energy costs limited discounting and maintained slight price firmness.
For the Quarter Ending September 2025
APAC
- In India, the Oxcarbazepine Price Index fell by 15.03% quarter-over-quarter, reflecting destocking and oversupply pressures.
- The average Oxcarbazepine price for the quarter was approximately USD 54919.74/MT measured across Vadodara-origin contracts.
- Oxcarbazepine Spot Price weakened in September as distributors discounted to reduce elevated national inventory levels.
- Oxcarbazepine Production Cost Trend rose from higher solvent and intermediate prices alongside modest INR depreciation.
- Oxcarbazepine Demand Outlook stayed weak as formulators postponed purchases amid monsoon and year-end inventory adjustments.
- Oxcarbazepine Price Forecast signals mild recovery as fiscal year-end restocking supports tighter availability into Q4.
- Oxcarbazepine Price Index volatility reflected shipment delays, container scarcity, and selective producer discipline on volumes.
- Export demand softened, pressuring domestic margins while traders aggressively liquidated stocks to maintain cash flow.
Why did the price of Oxcarbazepine change in September 2025 in APAC?
- Elevated inventories and dealer destocking in September amplified downward pressure on domestic Oxcarbazepine Price Index.
- Weak downstream demand and fiscal-year purchasing pauses reduced offtake, depressing Oxcarbazepine Spot Price momentum significantly.
- Rising solvent costs and INR depreciation increased Oxcarbazepine Production Cost Trend, sellers discounted protecting liquidity.
North America
- In the United States, the Oxcarbazepine Price Index declined, pressured by muted pharmaceutical formulation activity and heavy distributor inventories.
- Spot prices softened in September as contract buyers delayed offtakes amid slower API consumption and inventory balancing.
- The Oxcarbazepine production cost trend edged higher due to elevated solvent input costs and marginal increases in energy rates.
- Demand outlook remained weak as generic drug manufacturers minimized purchases, anticipating year-end price normalization.
- Price volatility stayed contained, supported by stable logistics, steady feedstock availability, and balanced supply discipline among key producers.
- Export orders into Canada and Mexico were limited, further weighing on domestic margins.
- Currency stability and lower freight costs limited pressure, maintaining a narrow trading range through late Q3.
Europe
- In Europe, the Oxcarbazepine Price Index fell further driven by subdued demand from formulation hubs.
- Spot prices weakened across key markets as distributors offered discounts to liquidate slow-moving inventories.
- The Oxcarbazepine production cost trend increased marginally amid higher energy tariffs and elevated intermediate costs.
- Demand outlook stayed bearish, with most formulators deferring purchases amid persistent inflationary pressure and weak export orders.
- Currency appreciation of the Euro versus the USD reduced import costs slightly, adding mild downward pressure on landed prices.
- Logistics and supply chain operations remained steady, preventing sharp supply disruptions or speculative price movements.
- Producer discipline and inventory clearance strategies defined pricing behavior through the end of September.
